Sinovac Biotech Key stats and ratios

Sinovac Biotech Ltd. ( NASDAQ:SVA). Last Market Price: 2.97, Change: +0.61, % Change: (25.85%). Shares trade in the range of 2.42 – 3.33 dollars. It has a market capitalization of 162.28M dollars, making it a Small Cap Stock and has 54.64M outstanding shares. The company has a beta of 2.25, indicating, the stock to be more volatile than the market. As per the most recent quarterly report, the net income per share (EPS) is -0.2. It operates in Healthcare sector and belongs to Biotechnology and Drugs industry. Percentage shares held by institutional investors is 49%. The company has a 52 week high of $ 5.06 and a 52 week low of $ 1.91. Average volumes of shares traded daily are 130,208. Volume traded in the last session was at 1,190,000, 9.14 times the average volume.

For Q2 (Jun ’11), It had a Net profit margin of 11.99%, an Operating margin of 20.00%. Other Key stats and ratios are : Return on average assets of 3.71%, Return on average equity of 4.21%. The organization has an employee strength of 483

Senior management consists of Weidong Yin, ( Age: 46 ), as Chairman of the Board, President, Chief Executive Officer, Secretary, Nan Wang, ( Age: 44 ), as Interim Chief Financial Officer, VP – Business Development; General Manager of Sinovac Dalian and Xia Ming, ( Age: 37 ), as Vice President – Sales and Marketing of Sinovac Beijing. Zhenshan Zhang, ( Age: 36 ), as General Manager of Tanghsn Yian Kenneth Lee as Director

Consensus Recommendation is a Hold.

Estimate for sales for the Quarter Ending Sep-11 show a mean of 12.10 million dollars, an estimate high of 12.10 million dollars and an estimate low of 12.10 million dollars. A year ago the figures stood at 24.69 million dollars.

Estimate for sales for the Quarter Ending Dec-11 show a mean of 27.24 million dollars, an estimate high of 27.24 million dollars and an estimate low of 27.24 million dollars. A year ago the figures stood at 43.42 million dollars.

Estimate for EPS for the Quarter Ending Sep-11 show a mean of 0.00 dollars, an estimate high of 0.02 dollars and an estimate low of -0.01 dollars. A year ago the figures stood at 0.08 dollars.

Estimate for EPS for the Quarter Ending Dec-11 show a mean of 0.19 dollars, an estimate high of 0.24 dollars and an estimate low of 0.14 dollars. A year ago the figures stood at 0.08 dollars.

Sales for Quarter Ending Jun-11 was estimated at 5.66 million dollars, however the actual sales figure stood at 15.66 million dollars, 9.99 million dollars more than estimates.

Sales for Quarter Ending Mar-11 was estimated at 4.52 million dollars, however the actual sales figure stood at 4.68 million dollars, 0.16 million dollars more than estimates.

Post Written By: Ed Liston Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications. He is widely quoted in various financial publications on the Internet. When Ed is not writing about stocks, investing in stocks, talking about stocks, or otherwise doing something stock related, he likes to go sailing and fishing in his yacht.